Proscia has received a new 510(k) clearance from the U.S. Food and Drug Administration for its Concentriq AP-Dx digital pathology platform. The clearance adds compatibility with the Leica Aperio GT 450 DX slide scanner, enables cloud deployment, and includes a Predetermined Change Control Plan that lets Proscia expand the platform's interoperability without a new 510(k) submission for every future addition. Concentriq AP-Dx is used for primary diagnosis in laboratories ranging from small reference labs to large hospital systems.
The clearance builds on Concentriq AP-Dx's original FDA authorization from February 2024, which paired the software with the Hamamatsu NanoZoomer S360MD slide scanner. The platform is also CE-marked under the European Union's In Vitro Diagnostic Regulation. Adding a second FDA-cleared scanner option gives laboratories more flexibility in how they build out a digital pathology workflow.
What's new in this FDA clearance
The updated clearance covers several distinct additions rather than a single feature:
- Compatibility with the Leica Aperio GT 450 DX whole slide scanner, a high-throughput, 450-slide-capacity system with continuous rack loading
- Support for cloud deployment of the Concentriq AP-Dx platform
- A Predetermined Change Control Plan covering future scanners, image formats, and displays
- Continued compatibility with the Hamamatsu NanoZoomer S360MD scanner from the platform's original 2024 clearance
Ian Cadieux, Proscia's head of quality and regulatory, framed the update around long-term platform commitments. "Laboratories choose a digital pathology platform with the expectation that it will sit at the center of their practice for years to come," Cadieux said. "The PCCP helps us to protect that investment, giving customers confidence that Concentriq AP-Dx will continue to be an interoperable foundation as their needs evolve."
Why a change control plan matters for laboratory buyers
A Predetermined Change Control Plan, or PCCP, is a relatively new regulatory mechanism. Congress authorized it through the 2022 Food and Drug Omnibus Reform Act, and the FDA finalized its guidance for AI-enabled device software in December 2024. Under a PCCP, a manufacturer specifies planned modifications in advance, and the FDA reviews and authorizes that plan alongside the device's original submission.
Once authorized, changes that fall within the plan can move forward without a new marketing submission, provided the manufacturer follows the agreed methods for validation, labeling, and quality oversight. For a digital pathology buyer, that distinction is practical rather than academic. A platform's ability to add scanners, monitors, or file formats without waiting on repeat FDA review can shorten the gap between a vendor's roadmap and what a lab can actually deploy.
The pathologist shortage behind the push for interoperability
Proscia's announcement points to workforce pressure as a driver. More than 2.1 million Americans are projected to be diagnosed with cancer this year, a figure that lines up with the American Cancer Society's Cancer Facts & Figures 2026 report, which puts the estimate at roughly 2,114,850 new cases nationwide. At the same time, the American Society for Clinical Pathology points to federal projections showing a 7 percent decline in the supply of pathologists against a 16 percent rise in demand by 2037.
Advanced Lab Management Certificate
The Advanced Lab Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
That combination of rising case volume and a shrinking specialist pool is a familiar one across the broader clinical laboratory, where many facilities are navigating similar staffing pressure and looking to automation as a partial offset. Digital pathology has been pitched for years as one lever labs can pull, letting pathologists sign out cases remotely and share expertise across sites.
Even so, adoption has been slower than the technology's advocates once expected. KLAS Research's Digital Pathology 2026 report on the U.S. market found that many laboratories remain stuck in early implementation phases, with workflow and change management challenges often outweighing concerns about the software itself.
How Concentriq AP-Dx compares in a crowded market
Concentriq AP-Dx is not the only FDA-cleared option for primary diagnosis. Philips brought the first cleared system to market in 2017, and Leica Biosystems, Hamamatsu, and Roche Diagnostics have each added cleared scanner and software combinations since then. The table below shows when each major whole slide imaging scanner earned its own FDA clearance for primary diagnosis, and where Concentriq AP-Dx fits.
| Scanner | Vendor | FDA clearance for primary diagnosis | Works with Concentriq AP-Dx |
|---|---|---|---|
| IntelliSite Pathology Solution | Philips | 2017 | No |
| Aperio AT2 DX | Leica Biosystems | 2019 | No |
| NanoZoomer S360MD | Hamamatsu Photonics | 2022 | Yes, since February 2024 |
| VENTANA DP 200 / DP 600 | Roche Diagnostics | 2024 | No |
| Aperio GT 450 DX | Leica Biosystems | 2024 | Yes, added August 2026 |
Rather than compete on scanner hardware, Proscia has positioned Concentriq as a software layer that works across multiple vendors' scanners. The company contrasts this with more closed, single-vendor ecosystems, and the approach appears to be resonating with customers. Proscia reported the highest overall performance score in KLAS Research's first comprehensive U.S. digital pathology report, and it says it was the only vendor in that report to earn top grades across all six customer experience categories KLAS tracks.
Want to stay up to date on the latest lab management news?
Proscia states that its platform serves laboratories managing roughly 12 million patient cases annually and works with 16 of the top 20 pharmaceutical companies. Those figures come from the company rather than an independent audit, so they are worth reading as vendor claims rather than verified statistics. Even so, they point to meaningful scale in a market that is still relatively young.
What this FDA clearance means for your lab
For a lab manager evaluating digital pathology, this clearance is less about one new scanner and more about the regulatory mechanism behind it. A PCCP is designed to make future hardware and format additions faster to implement, which could shorten the wait between a vendor's roadmap and what a lab can actually put into production.
That flexibility does not eliminate the harder questions that come with any digital pathology rollout. Labs considering Concentriq AP-Dx, or a competing platform, will still want to weigh scanner compatibility, cloud versus on-premises deployment, and how a vendor's change control plan actually gets exercised once it is authorized. Recent work on AI-assisted image analysis in cancer research is a reminder that the underlying technology keeps moving quickly, regardless of which regulatory pathway a vendor uses to keep pace.
